Press Release

PhRMA Statement on Peer Education Programs

PhRMA April 30, 2013

Washington, D.C. (October 21, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani [bio] today issued the following statement on peer education programs conducted by physicians on behalf of pharmaceutical research companies:

“Peer-to peer-information exchange improves the health of patients by providing physicians with practical knowledge and experience from their peers in using new and existing medicines. Doctors attend these sessions because they find the information valuable to their practice.

“Biopharmaceutical research companies only want to work with the most ethical healthcare professionals.

“Make no mistake, the very small minority of doctors who have engaged in inappropriate practices have no business being part of these sessions. In the rare instance when a speaker falls short of these high standards, companies take corrective action.

“The Food and Drug Administration (FDA) regulates the materials presented in these sessions and holds sponsoring companies accountable for their content. In addition, companies exceed federal standards through self regulation.

“The PhRMA Code on Interactions with Healthcare Professionals, which was strengthened in 2008, contains detailed provisions specific to the conduct and training of speakers. Under the Code, company decisions regarding the selection of healthcare professionals are based on defined criteria such as medical expertise, reputation, knowledge and experiences in a particular therapeutic area, and communication skills.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: